LONDON--(BUSINESS WIRE)--EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat focal refractory epilepsy, today announced it has raised a total of $10 million in seed funding. The financing was led by the UCL Technology Fund, with participation from Health Technology Holding..

伦敦--（商业新闻短讯）--EpilepsyGTx是一家专注于研究和开发治疗局灶性难治性癫痫的尖端基因疗法的生物技术公司，今天宣布它已筹集了总计1000万美元的种子资金。

The funds raised will be used to complete the preclinical studies for EpilepsyGTx’ lead gene therapy program EPY201, and to prepare a groundbreaking first-in-human, Phase 1/2a clinical study with EPY201 in focal refractory epilepsy.

筹集的资金将用于完成EpilepsyGTx的先导基因治疗计划EPY201的临床前研究，并用EPY201在局灶性难治性癫痫中进行开创性的首次人类1/2a期临床研究。

'This funding is a clear vote of confidence from our investors in our vision, the world-class science of the UCL Queen Square Institute of Neurology, and the transformative potential of EPY201 in focal refractory epilepsy. Our mission is to make patients with focal refractory epilepsy seizure-free,' said Nicolas Koebel, chief executive officer..

“这笔资金是我们投资者对我们的愿景、伦敦大学学院皇后广场神经病学研究所的世界级科学以及EPY201在局灶性难治性癫痫中的变革潜力的明确信任投票。首席执行官尼古拉斯·科贝尔（NicolasKoebel）说，我们的任务是使局灶性难治性癫痫患者免于癫痫发作。

Simon Goldman, Partner at AlbionVC, manager of the UCL Technology Fund and EpilepsyGTx Board member, added, “EpilepsyGTx has an objectively world-leading pipeline of genetic therapies for a common and damaging neurological disorder with few treatment options, developed by a globally-renowned clinical, scientific and translational team at the UCL Queen Square Institute of Neurology.

AlbionVC合伙人、UCL技术基金经理、EpilepsyGTx董事会成员西蒙·戈德曼（SimonGoldman）补充道：“EpilepsyGTx拥有一条客观上世界领先的基因治疗管道，用于治疗一种常见且具有破坏性的神经系统疾病，几乎没有治疗选择，由UCL皇后广场神经病学研究所（Queen Square Institute of Neurology）的全球知名临床、科学和转化团队开发。

We are enormously pleased to have Nicolas Koebel on board as CEO, with a track record of building exceptional global biotech companies from inception to commercial launch. We are excited that this industry-leading team now has the opportunity to translate medicines that have the potential to change the lives of patients with epilepsy and other CNS disorders.”.

我们非常高兴有尼古拉斯·科贝尔（NicolasKoebel）担任首席执行官，从成立到商业启动，我们一直在打造卓越的全球生物技术公司。我们很高兴这个行业领先的团队现在有机会翻译有可能改变癫痫和其他中枢神经系统疾病患者生活的药物。”

EpilepsyGTx is a spinout company set up with the support of UCL’s commercialisation company UCL Business Ltd (UCLB). Caitriona O’Rourke, UCLB’s Business Manager for EpilepsyGTx commented: “We have been delighted to support Nicolas and his team on their commercialisation journey, and it’s terrific to see them reach this major funding milestone.

EpilepsyGTx是在UCL商业化公司UCL Business Ltd（UCLB）的支持下成立的一家衍生公司。UCLB癫痫SYGTX业务经理Caitriona O'Rourke评论道：“我们很高兴支持Nicolas及其团队的商业化进程，看到他们达到这一重大资金里程碑，真是太棒了。

We are excited by the commercial potential of this technology and its possible contribution to improve the lives of people with focal refractory epilepsy.”.

我们对这项技术的商业潜力及其对改善局灶性难治性癫痫患者生活的可能贡献感到兴奋。”

Michele Gaiotto, Managing Director at Health Technology Holding, stated, “We were highly impressed by the scientific strategy of the company and the credentials of the leadership team. The targeted, highly localized delivery of gene therapy is the right solution to treat focal refractory epilepsy, and is poised to make an enormous difference in the lives of millions of patients.”.

Health Technology Holding董事总经理米歇尔·盖奥托（Michele Gaiotto）表示：“公司的科学战略和领导团队的资质给我们留下了深刻的印象。基因治疗的有针对性，高度本地化是治疗局灶性难治性癫痫的正确解决方案，并有望为数百万患者的生活带来巨大变化。”

At EpilepsyGTx our mission is to make patients with focal refractory epilepsy seizure-free. We are developing a portfolio of cutting-edge gene therapies which are based on pioneering research from the UCL Queen Square Institute of Neurology. For more information, please visit: www.epilepsygtx.com

在EpilepsyGTx，我们的任务是使局灶性难治性癫痫患者免于癫痫发作。我们正在开发一系列前沿基因疗法，这些疗法基于伦敦大学学院皇后广场神经病学研究所的开创性研究。有关更多信息，请访问：www.epilepsygtx.com

About focal refractory epilepsy

关于局灶性难治性癫痫

Focal epilepsy describes a group of disorders in which patients experience seizures that arise from a specific part of the brain. If seizures persist despite trials of at least two tolerated and appropriately chosen antiseizure medicines, epilepsy is deemed refractory. Focal refractory epilepsy (or FRE) affects an estimated 2 million prevalent patients in the United States, the United Kingdom and the European Union, combined..

局灶性癫痫描述了一组疾病，其中患者经历了由大脑特定部分引起的癫痫发作。如果癫痫发作持续存在，尽管至少有两种耐受性和适当选择的抗癫痫药物进行了试验，癫痫被认为是难治性的。据估计，在美国、英国和欧盟，局灶性难治性癫痫（或FRE）总共影响200万流行患者。

About EPY201

关于EPY201

EPY201 is an investigational gene therapy targeting focal refractory epilepsy. EPY201 or AAV9-CAMK2A-EKC uses an AAV9 capsid, an engineered Kv1.1 potassium channel (or “EKC”) and a CAMK2A promoter. EPY201 is delivered directly to the target seizure focus (that is, the part of the brain causing seizures) by intraparenchymal administration..

EPY201是一种针对局灶性难治性癫痫的研究性基因疗法。EPY201或AAV9-CAMK2A-EKC使用AAV9衣壳，工程Kv1.1钾通道（或“EKC”）和CAMK2A启动子。EPY201通过实质内给药直接传递到目标癫痫发作灶（即引起癫痫发作的大脑部分）。

The UCL Technology Fund exists to help solve the world’s most pressing problems: healthy planet, healthy people and healthy work. It helps UCL innovators across the Physical and Life Sciences scale globally. The Fund supports UCL in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical commercial application.

UCL技术基金旨在帮助解决世界上最紧迫的问题：健康的地球、健康的人和健康的工作。它帮助全球物理和生命科学领域的UCL创新者。该基金支持UCL在从最初的概念验证到实际商业应用的整个发展过程中，充分发挥创新的潜力，这些创新具有突出的社会和市场影响前景。

The Fund is managed by AlbionVC in collaboration with UCL Business. For further information please visit: www.ucltf.co.uk.

该基金由AlbionVC与UCL Business合作管理。欲了解更多信息，请访问：www.ucltf.co.uk。